


HPLC, Hemoglobin A₂ and F Assay

The VARIANT™ II β -thalassemia Short Program is a fully-automated method for β -thalassemia and abnormal hemoglobin testing



About

TARGETED SUPPORTIVE ASSAY

Separates and determines area percentages for hemoglobins A₂ and F and provides qualitative determinations of abnormal hemoglobins.

Using high-performance liquid chromatography (HPLC), the system delivers precise quantitation of Hemoglobin A₂ and F, supporting the monitoring of patients with sickling disorders undergoing therapy.

SAMPLE

Use of low volume, whole blood collected in EDTA with no pre-processing or dilution.

Highlights

HEMOGLOBIN A₂ AND F DETERMINATIONS

The Variant II HPLC Hemoglobin A₂ and F Assay provides a reliable, automated solution for hemoglobin fractionation.

Using high-performance liquid chromatography (HPLC), the system delivers precise quantitation of Hemoglobin A₂ and F, supporting the monitoring of patients with sickling disorders undergoing therapy.

TARGETED THERAPIES

Supportive Assay for BCL Proprietary Microfluidic Platforms

Typical Uses

✓ CLINICAL ASSAY

Variant II β -thalassemia Short Program

